These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23371849)

  • 1. Early predictors of prolonged stay in a critical care unit following aneurysmal subarachnoid hemorrhage.
    Witiw CD; Ibrahim GM; Fallah A; Macdonald RL
    Neurocrit Care; 2013 Jun; 18(3):291-7. PubMed ID: 23371849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
    Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
    Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
    Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT
    Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
    Higashida RT; Bruder N; Gupta R; Guzman R; Hmissi A; Marr A; Mayer SA; Roux S; Weidauer S; Aldrich EF
    World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
    Song J; Xue YQ; Wang YJ; Xu P; Sun DK; Chen W
    World Neurosurg; 2019 Mar; 123():e235-e244. PubMed ID: 30496924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
    Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage.
    Aldrich EF; Higashida R; Hmissi A; Le EJ; Macdonald RL; Marr A; Mayer SA; Roux S; Bruder N
    J Neurosurg; 2020 May; 134(5):1553-1561. PubMed ID: 32442971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Method of aneurysm treatment does not affect clot clearance after aneurysmal subarachnoid hemorrhage.
    Ibrahim GM; Vachhrajani S; Ilodigwe D; Kassell NF; Mayer SA; Ruefenacht D; Schmiedek P; Weidauer S; Pasqualin A; Macdonald RL
    Neurosurgery; 2012 Jan; 70(1):102-9; discussion 109. PubMed ID: 21788917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.
    Wang X; Li YM; Li WQ; Huang CG; Lu YC; Hou LJ
    PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Neurological Outcomes Related to Aneurysmal Subarachnoid Hemorrhage and Onsite Access to Neurointerventional Radiology.
    Mogollon JP; Smoll NR; Panwar R
    World Neurosurg; 2018 May; 113():e29-e37. PubMed ID: 29410100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Frey A; Marr A; Roux S; Kassell NF
    Neurocrit Care; 2010 Dec; 13(3):416-24. PubMed ID: 20838933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
    Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
    J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient phenotypes associated with outcomes after aneurysmal subarachnoid hemorrhage: a principal component analysis.
    Ibrahim GM; Morgan BR; Macdonald RL
    Stroke; 2014 Mar; 45(3):670-6. PubMed ID: 24425125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of fluid balance and colloid administration on outcomes in patients with aneurysmal subarachnoid hemorrhage: a propensity score-matched analysis.
    Ibrahim GM; Macdonald RL
    Neurocrit Care; 2013 Oct; 19(2):140-9. PubMed ID: 23715669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic changes predict angiographic vasospasm after aneurysmal subarachnoid hemorrhage.
    Ibrahim GM; Macdonald RL
    Stroke; 2012 Aug; 43(8):2102-7. PubMed ID: 22678087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
    Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
    Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Hemodynamic Changes Based on Initial Color-Coding Angiography as a Predictor for Developing Subsequent Symptomatic Vasospasm After Aneurysmal Subarachnoid Hemorrhage.
    Burkhardt JK; Chen X; Winkler EA; Weiss M; Yue JK; Cooke DL; Kim H; Lawton MT
    World Neurosurg; 2018 Jan; 109():e363-e373. PubMed ID: 28987853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
    Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
    J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
    Macdonald RL; Kassell NF; Mayer S; Ruefenacht D; Schmiedek P; Weidauer S; Frey A; Roux S; Pasqualin A;
    Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
    Acta Neurochir Suppl; 2013; 115():27-31. PubMed ID: 22890639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.